Dark Forest Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Dark Forest Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-662	Closed	-$12K	–	1467
2022 Q1	$12K	Sell	662 -6,942	-91%	-$105K	﹤0.01%	973
2021 Q4	$124K	Buy	7,604 +6,285	+476%	+$105K	0.05%	310
2021 Q3	$37K	Buy	+1,319	New	+$37.6K	0.01%	648

Other funds holding RVNC

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Dark Forest Capital Management's RVNC Position: Q2 2022 in Review

Dark Forest Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2022, closing a stake of 662 shares — an estimated $12K sold.

Dark Forest Capital Management first reported a position in RVNC in Q3 2021 and held it in 3 quarters. The position peaked at $124K in Q4 2021. 161 funds tracked by Wall St. Rank hold RVNC as of Q2 2022.

Dark Forest Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
Dark Forest Capital Management sold 662 Revance Therapeutics, Inc. shares in Q2 2022, an estimated $12K.
Dark Forest Capital Management first reported a position in Revance Therapeutics, Inc. in Q3 2021 and held it in 3 quarters.
Dark Forest Capital Management's Revance Therapeutics, Inc. position peaked at $124K in Q4 2021.
161 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2022.

Based on Dark Forest Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.